Veru Inc Dossier - Source-backed chat

Veru Inc

VERUNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.44

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.66Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $45.4M

Enterprise Value $24.3M

Shares Outstanding 17.1M diluted

Next Earnings Date31 Mar 2027

Last ex-dividend28 Apr 2014

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Veru Inc. is a late clinical-stage biopharmaceutical company uniquely positioned at the intersection of cardiometabolic health and muscle preservation. The company's lead asset, enobosarm (an oral selective androgen receptor modulator, or SARM), is being developed to address a critical unmet need in the rapidly expanding GLP-1 weight loss market: preventing the loss of lean muscle mass and physical function during active weight reduction. By combining enobosarm with GLP-1 receptor agonists like semaglutide, Veru aims to deliver high-quality weight loss (selective fat loss while preserving muscle). The recent clinical supply agreement with Novo Nordisk to provide Wegovy® for the Phase 2b PLATEAU trial validates the therapeutic concept and significantly reduces trial costs. With a strengthened balance sheet following recent equity offerings and asset sales, Veru has a cash runway extending beyond its highly anticipated Q1 calendar year 2027 interim data readout, making it a compelling high-upside opportunity for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$24.00

Mean target$24.50

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.72

The Phase 2b PLATEAU trial fails to show a statistically significant benefit in preserving lean mass or physical function over semaglutide alone, or reveals unexpected safety and tolerability issues. Novo Nordisk declines further collaboration. The company's cash runway is depleted faster than anticipated, forcing highly dilutive equity financing under its shelf registration, and the stock faces downward pressure toward its 52-week low.

Base CaseCentral scenario

$23.00

Veru successfully completes enrollment for the Phase 2b PLATEAU trial. The 36-week interim analysis expected in Q1 calendar year 2027 shows positive trends in lean mass preservation and fat mass reduction, consistent with the previous QUALITY trial. The company maintains disciplined expense management, keeping its quarterly cash burn low, and successfully initiates Phase 3 planning with the FDA. The stock moves toward consensus analyst targets as clinical milestones are achieved.

Bull CaseUpside scenario

$15.00

The Phase 2b PLATEAU trial meets its primary and secondary endpoints, demonstrating that enobosarm 3mg combined with semaglutide significantly preserves lean muscle mass, enhances physical function, and accelerates selective fat loss compared to GLP-1 monotherapy. Novo Nordisk exercises its right of first negotiation, leading to a lucrative global co-development and commercialization partnership. The FDA fast-tracks the modified-release formulation of enobosarm for Phase 3 trials, and the company successfully leverages its clinical success to secure non-dilutive upfront milestone payments, driving substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strategic focus on the high-growth obesity market, specifically targeting muscle preservation which is a major limitation of current GLP-1 therapies.
Clinical supply agreement with Novo Nordisk for Wegovy® validates the therapeutic hypothesis and reduces clinical trial execution costs.
Strong cash position of $27.6 million as of March 31, 2026, providing a runway beyond the critical Q1 calendar year 2027 interim data readout.
FDA alignment on clinical endpoints, including the acceptance of incremental weight loss as a primary endpoint and bone mineral density as a surrogate endpoint.

Key Investment Risks

High binary clinical trial risk associated with the ongoing Phase 2b PLATEAU study.
Intense competition in the obesity and cardiometabolic space from large pharmaceutical companies with vastly superior resources.
Potential need for future dilutive capital raises if clinical development timelines are extended or if Phase 3 trials require substantial upfront investment.
Regulatory hurdles and uncertainties inherent in securing FDA approval for novel drug combinations.

Thesis Invalidation Triggers

Failure of the Phase 2b PLATEAU trial to meet its interim efficacy endpoints for lean mass preservation in Q1 calendar year 2027.
Safety signals or adverse events leading to a clinical hold on enobosarm by the FDA.
Inability to secure additional funding or strategic partnerships prior to the depletion of the current cash runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.